Generic Name and Formulations:
Liraglutide 6mg/mL; soln for SC inj.
Search Premium Monographs
Have a product inquiry? Access comprehensive and accurate pharmaceutical Medical Information
Indications for VICTOZA:
As adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus (T2DM). To reduce the risk of major adverse CV events (eg, CV death, non-fatal MI/stroke) in adults with T2DM and established CV disease.
Limitations Of use:
Not a substitute for insulin. Not for treating type 1 diabetes or diabetic ketoacidosis. Not studied in combination with prandial insulin.
Give by SC inj in abdomen, thigh, or upper arm once daily. Initially 0.6mg/day for 1 week, then 1.2mg/day; may increase to 1.8mg/day. If >3 days elapsed since last dose, reinitiate at 0.6mg/day, then titrate.
<18yrs: not recommended.
History (personal or family) of medullary thyroid carcinoma. Multiple endocrine neoplasia syndrome type 2.
Risk of thyroid C-cell tumors.
Risk of thyroid C-cell tumors; inform patients of potential risk and symptoms. Discontinue if pancreatitis is suspected; do not restart if confirmed. History of pancreatitis: limited data. Evaluate if cholelithiasis is suspected. Do not reuse or share pens or needles between patients. History of anaphylaxis or angioedema with other GLP-1 receptor agonist. Discontinue if hypersensitivity reactions occur. Renal impairment: caution with initiating or escalating doses. Hepatic impairment: use with caution (limited data). Dehydration. Gastroparesis: not studied. Pregnancy. Nursing mothers.
Glucagon-like peptide-1 (GLP-1) receptor agonist.
Concomitant insulin; administer as separate injections not adjacent to each other. Hypoglycemia with sulfonylureas or insulin (consider reducing their doses). May affect absorption of concomitant oral drugs (delayed gastric emptying); caution.
Nausea, diarrhea, headache, vomiting, decreased appetite, dyspepsia, constipation, immunogenicity reactions (eg, urticaria); rare: pancreatitis, papillary thyroid carcinoma, hypersensitivity reactions.
Multi-dose, pre-filled pens (3mL)—2, 3
Neurology Advisor Articles
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Serious Adverse Events Profile for Cladribine Confirmed With Extended Data
- Patients With Multiple Sclerosis Face Greater Infection Risk
- Ozanimod Reduces Severe Relapses in Multiple Sclerosis More Than Interferon Beta-1a